Kenvue (NYSE:KVUE) Issues Earnings Results, Hits Estimates

Kenvue (NYSE:KVUE) announced its quarterly earnings data on Friday. The company reported $0.29 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.29, FiscalAI reports. Kenvue had a return on equity of 21.22% and a net margin of 10.76%. The business had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.86 billion. During the same quarter in the previous year, the business earned $0.28 earnings per share. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year.

Kenvue Price Performance

NYSE:KVUE traded down $0.30 on Friday, reaching $19.26. 66,594,959 shares of the company’s stock traded hands, compared to its average volume of 27,001,805. The firm has a market cap of $36.99 billion, a PE ratio of 22.14, a P/E/G ratio of 1.77 and a beta of 0.48. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. The stock has a 50-day simple moving average of $18.39 and a 200-day simple moving average of $18.18. Kenvue has a 12 month low of $14.06 and a 12 month high of $20.13.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 2nd. Stockholders of record on Monday, September 21st were given a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. The ex-dividend date was Monday, September 21st. Kenvue’s dividend payout ratio (DPR) is presently 96.55%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on KVUE shares. HSBC dropped their price target on shares of Kenvue from $20.00 to $19.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Wall Street Zen cut shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. UBS Group decreased their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Zacks Research cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kenvue in a research report on Friday, September 11th. Thirteen investment analysts have rated the stock with a Hold rating. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $19.33.

More Kenvue News

Here are the key news stories impacting Kenvue this week:

• Positive Sentiment: Revenue increased 3.2% year over year to $3.89 billion, exceeding the roughly $3.86 billion consensus estimate. Management cited continued growth in Self Care and Essential Health, productivity initiatives, margin expansion and strong cash generation. Kenvue Reports Third Quarter 2026 Results
• Positive Sentiment: Reported earnings were $0.29 per share, up from $0.28 a year earlier. Zacks characterized the result as slightly ahead of its $0.28 consensus estimate, while other coverage said profit fell short of expectations, suggesting the market is focused on the exact earnings measure and guidance. Kenvue Surpasses Q3 Earnings Estimates
• Positive Sentiment: The quarterly performance represents Kenvue’s fourth consecutive quarter of net and organic sales growth, supporting management’s efforts to rebuild momentum across its consumer-health brands. Kenvue Profit, Revenue Rise as Turnaround Efforts Continue
• Neutral Sentiment: Kenvue’s results arrive as its approximately $40 billion acquisition by Kimberly-Clark approaches closing. The deal may provide strategic support, but investors remain focused on execution, integration and the turnaround’s durability. Kenvue Q3 2026 Revenue Beats as Kimberly-Clark Deal Nears Close
• Negative Sentiment: The conflicting earnings headlines indicate that profit performance did not clearly exceed investor expectations, even though revenue beat forecasts. Earlier concerns about inflation and cautious consumer spending also remain potential pressures on margins and demand. Kenvue Misses Third-Quarter Profit Expectations

Kenvue Company Profile

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.